Literature DB >> 11455753

Systemic therapy for rosacea: focus on oral antibiotic therapy and safety.

J Q Del Rosso1.   

Abstract

Although potentially significant adverse reactions and drug interactions have been reported in association with erythromycin, oral tetracyclines, and trimethoprim-sulfamethoxazole, overall these agents are associated with excellent safety profiles, especially considering their widespread use over many years. It must be considered that when these antibiotics are used for the treatment of rosacea and also for acne vulgaris, their use is on a long-term basis rather than their typical short-course regimens for most infectious diseases. As a result, dermatologists prescribing these agents may feel assured that most patients will not encounter any significant problems, but they do need to be aware of potential adverse reactions to allow for early recognition and discontinuation of the offending drug when needed. Early recognition also allows for favorable management of adverse reactions. In addition, potentially significant drug interactions may be recognized by obtaining a thorough medical history and avoiding combinations of drugs that may interact unfavorably. Fortunately, there are several choices that allow us to individually select a treatment regimen that is optimal for the individual patient, allowing for effective control of rosacea.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11455753

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  9 in total

1.  Use of Oral Doxycycline for Community-acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA) Infections.

Authors:  Sanjay Bhambri; Grace Kim
Journal:  J Clin Aesthet Dermatol       Date:  2009-04

2.  Chronic administration of oral trimethoprim-sulfamethoxazole for acne vulgaris.

Authors:  Morgan McCarty; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2011-08

Review 3.  Oral Doxycycline in the Management of Acne Vulgaris: Current Perspectives on Clinical Use and Recent Findings with a New Double-scored Small Tablet Formulation.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2015-05

Review 4.  Macrolides in chronic inflammatory skin disorders.

Authors:  Abdullateef A Alzolibani; Khaled Zedan
Journal:  Mediators Inflamm       Date:  2012-05-17       Impact factor: 4.711

5.  Safety and efficacy of doxycycline in the treatment of rosacea.

Authors:  Sheila Valentín; Adisbeth Morales; Jorge L Sánchez; Abimael Rivera
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-08-12

6.  Oral azithromycin for treatment of intractable rosacea.

Authors:  Jae-Hong Kim; Yoon Seok Oh; Eung Ho Choi
Journal:  J Korean Med Sci       Date:  2011-04-21       Impact factor: 2.153

Review 7.  Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments.

Authors:  Martin Steinhoff; Marc Vocanson; Johannes J Voegel; Feriel Hacini-Rachinel; Gregor Schäfer
Journal:  Adv Ther       Date:  2016-07-18       Impact factor: 3.845

8.  Anti-Brucella activity of Caryopteris mongolica Bunge root extract against Brucella melitensis infection in mice.

Authors:  Tsevelmaa N; Narangerel B; Odgerel O; Dariimaa D; Batkhuu J
Journal:  BMC Complement Altern Med       Date:  2018-05-03       Impact factor: 3.659

9.  Patient Visits and Prescribing Patterns Associated with Rosacea in Korea: A Real-World Retrospective Study Based on Electronic Medical Records.

Authors:  Yu Ri Woo; Hyun Jeong Ju; Jung Min Bae; Minah Cho; Sang Hyun Cho; Hei Sung Kim
Journal:  J Clin Med       Date:  2022-03-17       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.